|Date||Analyst Firm||Analyst Name||Action||Rating||Action Price||Prior Price||Target|
You can purchase shares of Apellis Pharmaceuticals (NASDAQ: APLS) through any online brokerage.
The latest price target for Apellis Pharmaceuticals (NASDAQ: APLS) was reported by Citigroup on November 24, 2021. The analyst firm set a price target for 72.00 expecting APLS to rise to within 12 months (a possible 65.37% upside). 21 analyst firms have reported ratings in the last year.
The stock price for Apellis Pharmaceuticals (NASDAQ: APLS) is $43.54 last updated Fri Nov 26 2021 18:00:04 GMT+0000 (Coordinated Universal Time).
There are no upcoming dividends for Apellis Pharmaceuticals.
Apellis Pharmaceuticals’s $Q4 earnings are confirmed for after-market on February 24, 2022.
There is no upcoming split for Apellis Pharmaceuticals.
Apellis Pharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.